| 1 |
35156195 | In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B-Cell Lymphoma. | 2022 Jul |
1 |
| 2 |
35610089 | Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19+ hematologic indications. | 2022 May 21 |
1 |
| 3 |
35619325 | Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. | 2022 May 26 |
1 |
| 4 |
34030548 | Lisocabtagene Maraleucel for the treatment of B-cell lymphoma. | 2021 Sep |
1 |
| 5 |
34125421 | Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma. | 2021 Dec |
2 |
| 6 |
34216384 | Correction to: Population Cellular Kinetics of Lisocabtagene Maraleucel, an Autologous CD19-Directed Chimeric Antigen Receptor T-Cell Product, in Patients with Relapsed/Refractory Large B-Cell Lymphoma. | 2021 Dec |
1 |
| 7 |
34699774 | Lisocabtagene maraleucel in relapsed or refractory diffuse large B cell lymphoma: What is the evidence? | 2021 Oct 18 |
1 |